Nonalcoholic fatty liver disease (NAFLD) has affected more than one-fourth of the global population, thus emerging as a worldwide health and economic burden. The common causes of death in patients with NAFLD include cardiovascular disease (CVD), decompensation, and hepatocellular carcinoma (HCC). However, identifying the risk of these complications in patients with NAFLD remains an unmet need in clinical practice.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761224PMC
http://dx.doi.org/10.1016/j.cgh.2021.07.021DOI Listing

Publication Analysis

Top Keywords

nonalcoholic fatty
8
fatty liver
8
liver disease
8
patients nafld
8
risk difference
4
difference liver-related
4
liver-related cardiovascular
4
cardiovascular events
4
events liver
4
liver fibrosis
4

Similar Publications

Background and aim Non-alcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction-associated steatotic liver disease (MASLD), is more common in people with type-2 diabetes mellitus (T2DM) than in people without diabetes mellitus (non-DM). This disease can lead to cirrhosis or hepatic cancer. There is limited data on NAFLD prevalence and the level of risk of fibrosis in Bangladeshi individuals.

View Article and Find Full Text PDF

Targeting immune cellular populations and transcription factors: unraveling the therapeutic potential of JQF for NAFLD.

Front Immunol

January 2025

Institute of Metabolic Diseases, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

Background: Non-alcoholic fatty liver disease (NAFLD) constitutes the most prevalent chronic liver disease worldwide. Progression to non-alcoholic steatohepatitis (NASH), the immune cell reservoir within the liver undergoes remodeling, exacerbating liver inflammation and potentially leading to liver fibrosis. Jiangtang Qingre Formula (JQF) is an effective prescription for the clinical treatment of NAFLD.

View Article and Find Full Text PDF

Background: Non-alcoholic fatty liver disease (NAFLD) is a widespread liver condition associated with diabetes, metabolic syndrome, and cardiovascular diseases, yet public awareness remains low. Early detection of risk factors is crucial, but liver biopsy, the diagnostic gold standard, is invasive and costly. Non-invasive anthropometric indices provide a safer alternative.

View Article and Find Full Text PDF

Background: Hyperuricemia and non-alcoholic fatty pancreas disease (NAFPD) are prevalent metabolic diseases, but the relationship between them remains underexplored.

Methods: Eighteen Sprague-Dawley rats were randomly assigned to three groups: normal (CON), high-fat (PO), and high-fat high-uric acid (PH). After 12 weeks, serum uric acid (SUA) and triacylglycerol levels were measured.

View Article and Find Full Text PDF

Non-alcoholic fatty liver disease is a strong predictor of carotid high-risk plaques as assessed by high-resolution magnetic resonance imaging.

Quant Imaging Med Surg

January 2025

Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong University, Jinan, China.

Background: Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease with a high prevalence. Recent data suggest that NAFLD may be an independent risk factor for cardiovascular disease (CVD). This study aimed to investigate the association between NAFLD and carotid high-risk plaque (HRP) as assessed by high-resolution magnetic resonance imaging (MRI), and to examine the diagnostic value of NAFLD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!